Zobrazeno 1 - 10
of 226
pro vyhledávání: '"Hirokazu Shoji"'
Autor:
Toru Kadono, Satoru Iwasa, Toshiharu Hirose, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Atsuo Takashima, Ken Kato
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Background Nivolumab was approved for the treatment of advanced gastric cancer in 2017 in Japan. The aim of this study was to assess the impact of nivolumab in a real‐world clinical setting. Methods This single‐institutional retrospectiv
Externí odkaz:
https://doaj.org/article/fe41231595f14b45a5600e716b2861f8
Autor:
Hiroyuki Arai, Takashi Tsuda, Yu Sunakawa, Mototsugu Shimokawa, Kohei Akiyoshi, Shinya Tokunaga, Hirokazu Shoji, Kenji Kunieda, Masahito Kotaka, Toshihiko Matsumoto, Yusuke Nagata, Takuro Mizukami, Fumitaka Mizuki, Kathleen D. Danenberg, Narikazu Boku, Takako Eguchi Nakajima
Publikováno v:
Cancer Medicine, Vol 13, Iss 7, Pp n/a-n/a (2024)
Abstract Background Long‐term anti‐EGFR antibody treatment increases the risk of severe dermatologic toxicities. This single‐arm, phase II trial aimed to investigate the strategy of switching from cetuximab to bevacizumab in combination with FO
Externí odkaz:
https://doaj.org/article/f1dd28fe734a4a8888bd792971f6399b
Autor:
Naoki Takahashi, Hirokazu Shoji, Kengo Nagashima, Hiroshi Imazeki, Narikazu Boku, Takeshi Kawakami, Kei Muro, Takeru Wakatsuki, Chie Kudo-Saito, Yukiya Narita, Kai Tsugaru, Yusuke Amanuma, Naohiro Okano, Yoshiyuki Yamamoto, Rika Kizawa, Kazunori Aoki
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/907a904781714c80bf6d47dac396da55
Autor:
Toru Kadono, Satoru Iwasa, Kengo Nagashima, Kotoe Oshima, Shun Yamamoto, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Yoshitaka Honma, Atsuo Takashima, Ken Kato, Toshikazu Ushijima, Narikazu Boku
Publikováno v:
Cancer Medicine, Vol 12, Iss 8, Pp 9322-9331 (2023)
Abstract Background While the efficacy of immune checkpoint inhibitors (ICIs) reportedly varies among metastatic sites and progression patterns (classified as systemic progression [SP] or mixed progression [MP]), the clinical efficacy of ICIs against
Externí odkaz:
https://doaj.org/article/ede32e6300aa451ea9bc656aaed18946
Autor:
Hiroki Osumi, Atsuo Takashima, Akira Ooki, Yuri Yoshinari, Takeru Wakatsuki, Hidekazu Hirano, Izuma Nakayama, Natsuko Okita, Ryoichi Sawada, Kota Ouchi, Koshiro Fukuda, Shota Fukuoka, Mariko Ogura, Daisuke Takahari, Keisho Chin, Hirokazu Shoji, Ken Kato, Naoki Ishizuka, Narikazu Boku, Kensei Yamaguchi, Eiji Shinozaki
Publikováno v:
Translational Oncology, Vol 35, Iss , Pp 101718- (2023)
Purpose: As circulating tumor DNA (ctDNA) measurement becomes more widespread, the “NeoRAS” phenomenon, where tissue rat sarcoma viral oncogene homolog (RAS) status converts from mutant (MT) to wild-type (WT) after treatment in metastatic colorec
Externí odkaz:
https://doaj.org/article/2dd4356f4b714e61ada692c8cdb096f1
Autor:
Yosui Nojima, Masahiko Aoki, Suyong Re, Hidekazu Hirano, Yuichi Abe, Ryohei Narumi, Satoshi Muraoka, Hirokazu Shoji, Kazufumi Honda, Takeshi Tomonaga, Kenji Mizuguchi, Narikazu Boku, Jun Adachi
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 21, Iss , Pp 2172-2187 (2023)
Apatinib is known to be a highly selective vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with anti-angiogenic and anti-tumor properties. In a phase III study, the objective response rate to apatinib was low. It remains unclear why
Externí odkaz:
https://doaj.org/article/96f2d6f634004bf692af38e6773e75d9
Autor:
Hidekazu Hirano, Yuichi Abe, Yosui Nojima, Masahiko Aoki, Hirokazu Shoji, Junko Isoyama, Kazufumi Honda, Narikazu Boku, Kenji Mizuguchi, Takeshi Tomonaga, Jun Adachi
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-13 (2022)
Abstract Phosphoproteomic analysis expands our understanding of cancer biology. However, the feasibility of phosphoproteomic analysis using endoscopically collected tumor samples, especially with regards to dynamic changes upon drug treatment, remain
Externí odkaz:
https://doaj.org/article/23b1b93b6df84053b303f6da1b5e6546
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Despite the clinical outcomes being extremely limited, blocking immune inhibitory checkpoint pathways has been in the spotlight as a promising strategy for treating gastrointestinal cancer. However, a distinct strategy for the successful treatment is
Externí odkaz:
https://doaj.org/article/a023ecd5d8b5432a89b86bae5a4fe430
Autor:
Shigemasa Takamizawa, Hirokazu Shoji, Hidekazu Hirano, Koji Izutsu, Shun Yamamoto, Satoru Iwasa, Yoshitaka Honma, Natsuko Okita, Atsuo Takashima, Ken Kato, Narikazu Boku
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 1, Pp 85-89 (2021)
Severe thrombocytopenia is a rare adverse event of panitumumab. Here, we report the first patient with metastatic colorectal cancer who developed severe thrombocytopenia, diagnosed as panitumumab-associated drug-induced immune thrombocytopenia (DITP)
Externí odkaz:
https://doaj.org/article/f7f9deb3fbdd495a9e8697a053be6d2d
Autor:
Kotoe Oshima, Hidekazu Hirano, Hirokazu Shoji, Satoru Iwasa, Natsuko Okita, Atsuo Takashima, Narikazu Boku
Publikováno v:
PLoS ONE, Vol 17, Iss 6 (2022)
Background Trifluridine/tipiracil (TFTD), with or without bevacizumab (Bev), and regorafenib are salvage chemotherapy options for metastatic colorectal cancer (mCRC). Here, we examined the influence of precedent drug on the efficacy of subsequent dru
Externí odkaz:
https://doaj.org/article/23096a332ce14b679e99eae3943fe4c7